Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

MSer – A new, neutral descriptor for someone with multiple sclerosis
Therapeutic efficacy of IL-17 neutralization in murine experimental autoimmune encephalomyelitis.
A Web-based tool for personalized prediction of long-term disease course in patients with multiple sclerosis.
Comparing routine neurorehabilitation program with trunk exercises based on Bobath concept in multiple sclerosis: Pilot study.
In vivo vs. ex vivo Magnetic Resonance Imaging In Mice.
Disclosing the diagnosis of multiple sclerosis: The Profile Project.
Fingolimod increases brain-derived neurotrophic factor levels and ameliorates amyloid β-induced memory impairment.
Back on the scent: the olfactory system in CNS demyelinating diseases.
Synthon Announces Successful Outcomes from the Open-label extension of the Phase III GATE Study of Synthon’s Glatiramer Acetate
Myelin debris regulates inflammatory responses in an experimental demyelination animal model and multiple sclerosis lesions.
Detection of multiple sclerosis from exhaled breath using bilayers of polycyclic aromatic hydrocarbons and single-wall carbon nanotubes.
Social cognition in pediatric-onset multiple sclerosis (MS).
Progressive multifocal leukoencephalopathy: new concepts.
Immune Therapeutics, Inc. Announces Agreement with KRS Global Biotechnology, Inc.
Serum and CSF measles antibody levels increase over time in patients with multiple sclerosis or clinically isolated syndrome.
Periventricular Demyelination and Axonal Pathology Is Associated with Subependymal Virus Spread in a Murine Model for Multiple Sclerosis.
Differences in Diffusion Tensor Imaging-Derived Metrics in the Corpus Callosum of Patients With Multiple Sclerosis Without and With Gadolinium-Enhancing Cerebral Lesions.
Shifting imaging targets in multiple sclerosis: From inflammation to neurodegeneration.
Natalizumab in relapsing-remitting multiple sclerosis.
Venocentric Lesions: An MRI Marker of MS?
Sex as a determinant of relapse incidence and progressive course of multiple sclerosis.
Alemtuzumab: A new therapy for active relapsing-remitting multiple sclerosis.
Yoga for multiple sclerosis: a systematic review and meta-analysis.
Update on the Autoimmune Pathology of Multiple Sclerosis: B-Cells as Disease-Drivers and Therapeutic Targets.
Prevention and diminished expression of experimental autoimmune encephalomyelitis by low dose naltrexone (LDN) or opioid growth factor (OGF) for an extended period: Therapeutic implications for multiple sclerosis.

Pages